March 11, 2020

Tahir Mahmood, Ph.D.
Chief Executive Officer
Applied Molecular Transport Inc.
1 Tower Place, Suite 850
South San Francisco, California 94080

       Re: Applied Molecular Transport Inc.
           Draft Registration Statement on Form S-1
           Confidentially Submitted on February 13, 2020
           CIK No. 0001801777

Dear Mr. Mahmood:

       We have reviewed your draft registration statement and have the
following comments. In
some of our comments, we may ask you to provide us with information so we may
better
understand your disclosure.

       Please respond to this letter by providing the requested information and
either submitting
an amended draft registration statement or publicly filing your registration
statement on
EDGAR. If you do not believe our comments apply to your facts and circumstances
or do not
believe an amendment is appropriate, please tell us why in your response.

      After reviewing the information you provide in response to these comments
and your
amended draft registration statement or filed registration statement, we may
have additional
comments.

Form S-1 Confidentially Submitted on February 13, 2020

Prospectus Summary
Our Pipeline and Research Programs , page 2

1.     Noting the graphic illustration of your pipeline here and in your
Business section, please
       revise to identify to what the apparent second footnote relates, clarify
the meaning of the
       blue chevrons and ensure that the graphic depiction clearly reflects the
actual status of
       your programs or advise.
Liquidity and Capital Resources
Liquidity, page 86

2.     We note the disclosure on page 87 and elsewhere that you expect to incur
significant and
 Tahir Mahmood, Ph.D.
Applied Molecular Transport Inc.
March 11, 2020
Page 2
         increasing losses until regulatory approval is granted for your lead
product candidate, that
         regulatory approval is not guaranteed and may never be obtained and
that these conditions
         raise substantial doubt about your ability to continue as a going
concern. Please revise
         your Summary to summarize the doubts about your ability to continue as
a going concern.
         Also expand your Risk Factors to specifically address the associated
risks.
General

3.       Please revise to provide the disclosure required by Item 505 of
Regulation S-K.
4.       Please supplementally provide us with copies of all written
communications, as defined in
         Rule 405 under the Securities Act, that you or anyone authorized to do
so on your behalf
         present in reliance on Section 5(d) of the Securities Act, whether or
not they retain the
         communications.
        You may contact David Burton at 202-551-3626 or Vanessa Robertson at
202-551-3649
if you have questions regarding comments on the financial statements and
related
matters. Please contact Jessica Livingston at 202-551-3448 or Michael Clampitt
at 202-551-
3434 with any other questions.



FirstName LastNameTahir Mahmood, Ph.D.                         Sincerely,
Comapany NameApplied Molecular Transport Inc.
                                                               Division of
Corporation Finance
March 11, 2020 Page 2                                          Office of Life
Sciences
FirstName LastName